Drug Profile
Research programme: cell-based therapeutics - MaxCyte
Alternative Names: CAR therapy - MaxCyte; Chimeric Antigen Receptor T cell therapy - MaxCyte; Gene modified autologous cell therapies - Maxcyte; MaxCyte GT™Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator MaxCyte
- Developer Johns Hopkins University; MaxCyte
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Lymphoma; Solid tumours
- Discontinued Metabolic disorders; Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Lymphoma in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 23 Apr 2015 MaxCyte and John Hopkins University agree to co-develop Chimeric Antigen Receptor T cell therapy for Solid tumours